An indirect evidence of the role of this receptor in experimental malaria has been demonstrated by the in vivo blockade of CTLA-4 using specific monoclonal antibody, leading to an exacerbation of P. berghei-mediated immunopathology [19], [62]. This evidence concerns the gene CTLA4 and malaria.